Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation & Amortization (CF) (2016 - 2025)

ImmunityBio (IBRX) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 6.6% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, down 11.56% year-over-year, with the annual reading at $15.5 million for FY2025, 11.56% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $3.9 million at ImmunityBio, down from $4.0 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $5.2 million in Q4 2022, with the low at $3.0 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $4.2 million, with a median of $4.3 million recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) surged 61.5% in 2021, then decreased 15.94% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $3.6 million in 2021, then skyrocketed by 45.37% to $5.2 million in 2022, then decreased by 12.67% to $4.6 million in 2023, then decreased by 9.33% to $4.1 million in 2024, then decreased by 6.6% to $3.9 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $3.9 million, $4.0 million, and $3.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.